Patient-prosthesis mismatch after minimally invasive aortic valve replacement by Filip, Grzegorz et al.
www.kardiologiapolska.pl
Kardiologia Polska 2018; 76, 5: 908–910; DOI: 10.5603/KP.2018.0096
SHORT COMMUNICATION
Address for correspondence: 
Radoslaw Litwinowicz, MD, PhD, Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, and John Paul II Hospital, ul. Prądnicka 80,
31–202 Kraków, Poland, tel: +48 12 614 30 75, fax: +48 12 614 25 25, e-mail: radek.litwinowicz@gmail.com
Received: 20.11.2017 Accepted: 07.02.2018
Kardiologia Polska Copyright © Polish Cardiac Society 2018
Patient-prosthesis mismatch after minimally
invasive aortic valve replacement
Grzegorz Filip1*, Radoslaw Litwinowicz1*, Boguslaw Kapelak1, Magdalena Bryndza1, Magdalena Bartus2, 
Janusz Konstanty-Kalandyk1, Piotr Ceranowicz3, Maciej Brzezinski4, Sameer Gafoor5, Krzysztof Bartus1
1Department of Cardiovascular Surgery and Transplantology, Jagiellonian University and John Paul II Hospital, Krakow, Poland
2Department of Pharmacology, Jagiellonian University, Krakow, Poland
3Department of Physiology, Jagiellonian University, Krakow, Poland
4Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Gdansk, Poland
5CardioVascular Centre Frankfurt, Germany and Swedish Medical Centre Seattle, United States
*Grzegorz Filip and Radoslaw Litwinowicz are first authors of this manuscript and have contributed equally to the content of this paper.
INTRODUCTION
Compared to conventional aortic valve replacement (con-AVR, 
sternotomy), minimally invasive aortic valve replacement 
(mini-AVR) is associated with lower morbidity and mortality 
in high-risk patients. However, mini-AVR is technically chal-
lenging and more demanding. Limited access to the heart and 
a smaller operative field may lead to incorrect prosthesis size 
selection with greater risk of postoperative patient-prosthesis 
mismatch (PPM).
Patient-prosthesis mismatch occurs when the indexed ef-
fective orifice area (EOAi) of the implanted valve prosthesis is 
too small compared to the patient’s body surface area (BSA). 
PPM is a strong and independent predictor of cardiac events, 
left ventricular overload, and mortality [1, 2]. To date, the 
literature on PPM after mini-AVR is very limited.
The aim of our study was to analyse the prevalence of 
PPM after mini-AVR and the effect of PPM on post-operative 
transvalvular gradient.
METHODS
A total of 150 patients were enrolled in the study; 74 patients 
who underwent mini-AVR and 76 patients who underwent 
con-AVR. In each group all procedures were performed by 
a group of four experienced surgeons who decided which 
method to use as well as which prosthesis type and size. 
Patients were similar in terms of age, body mass index, sex, 
and comorbidities.
The EOAi was calculated by dividing the corresponding 
EOA of each valve type and size (registered in vitro values 
published by each manufacturer) by each patient’s BSA. 
BSA was calculated using methods described in a similar 
study [3]. PPM was defined as not clinically significant 
if the projected EOAi was > 0.85, moderate if it was 
> 0.65 and ≤ 0.85, and severe if it was ≤ 0.65 cm2/m2 [4].
RESULTS
Patients-prosthesis mismatch
Mean EOAi of all AVR patients was 0.97 cm2/m2, 
with PPM present in 31% (n = 46). Mean EOAi in the PPM 
group was 0.73 ± 0.8 cm2/m2 versus 1.07 ± 0.15 cm2/m2 
in the group without PPM (p < 0.001). Severe PPM 
(EOAi ≤ 0.65 cm2/m2) was present in 3.3% (n = 5), and mod-
erate PPM (0.65 cm2/m2 < EOAi ≤ 0.85 cm2/m2) was present 
in 27.3% of all AVR patients.
In mini-AVR, the incidence of PPM was 39%, with 
mean EOAi 0.91 ± 0.16 cm2/m2 and was higher compared 
to con-AVR, where the incidence of PPM was 22%, with 
mean EOAi 1.02 ± 0.23 cm2/m2 (p = 0.04 for PPM and 
p = 0.003 for EOAi).
Postoperative transprosthetic gradient
In all AVR patients, there was a significantly higher peak/mean 
postoperative transprosthetic gradient in the PPM group in 
comparison to the group without PPM (27.9/16.6 mmHg 
vs. 23.5/13.6 mmHg, p < 0.007 and p < 0.001). This was 
not the case in mini-AVR, where there was no difference in 
peak/mean postoperative transprosthetic gradient between 
the two groups (26.7/15.6 mmHg vs. 26.1/14.7 mmHg, 
p > 0.05). However, there was a significantly higher postoper-
ative peak/mean transprosthesis gradient in con-AVR patients 
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with PPM compared to those without PPM (30.4/18.5 mmHg 
vs. 21/12.7 mmHg, p < 0.002 and p < 0.001).
Aortic prosthesis size
In medium aortic prosthesis size a significantly lower mean 
EOAi was found in patients with mini-AVR in comparison to 
con-AVR patients (0.9 ± 0.16 cm2/m2 vs. 1.01 ± 0.24 cm2/m2, 
p = 0.007). There was no significant differences in mean 
EOAi, peak aortic valve gradient, or mean aortic valve gradi-
ent in other prosthesis sizes (Table 1).
DISCUSSION
Globally, the incidence of PPM after median sternotomy is 
estimated at between 20% and 70% [1]. Our study results are 
similar: overall moderate PPM was observed in about 27.3% 
of patients, and 3.3% of patients had severe PPM [5, 6]. In 
contrast to a previous study [5], we found that the incidence of 
PPM was higher in mini-AVR compared to con-AVR. This may 
be due to several reasons (Supplementary Figure 1 — see 
journal website).
The risk of PPM is strongly related to the size of implanted 
prosthetic valves [7, 8], with larger valves resulting in PPM 
less often than smaller valves. Differences in PPM prevalence 
were observed only in patients with medium-sized prostheses, 
where higher EOAi was observed in mini-AVR patients with 
PPM. Based on the mean value of EOAi in those patients, PPM 
may be categorised as moderate. A recent large meta-analysis 
found that severe PPM was associated with higher mortality 
[9]. It is possible that in mini-AVR surgeons were more often 
able to avoid implanting larger valves in favour of a medi- 
um-sized prosthesis, with acceptable postoperative haemody-
namic parameters. In our study, postoperative transprosthetic 
gradients were slightly lower in mini-AVR. There were also no 
differences in transprosthetic gradients in mini-AVR patients 
with PPM compared to those without PPM, in contrast to 
con-AVR, where higher gradients were observed in the PPM 
group. Therefore, the higher prevalence of PPM in mini-AVR 
had no impact on postoperative haemodynamic parameters.
The effective orifice area can be measured in a variety of 
ways, and may change over time. EOAi can be calculated using 
the manufacturer’s charts or echocardiographic data [5]. Due to 
the retrospective design of this analysis, the former method was 
used, which has been described elsewhere [4]. The EOAs re- 
ported by the manufacturer are based on in vitro models and their 
size may be overestimated in comparison with in vivo EOAs [5].
There are several surgical options to reduce the risk of 
PPM [10]. The first one involves aortic root enlargement 
procedures, which were not used in our study. Magruder et 
al. [5] show that aortic root enlargement procedures may also 
be successfully performed in mini-AVR patients to prevent 
PPM. The second option is the use of stentless bioprostheses, 
which present a better haemodynamic performance, but they 
are more challenging and increase the risk to the patient. 
New generation of stented bioprostheses is characterised by 
similar haemodynamic performance and an easier implanting 
technique [11]. There is no general recommendation for the 
preference of stentless bioprostheses. Most surgeons tend to 
implant stented valves in complicated cases and octogenarians 
because operative mortality and the stent durability are not 
worse than in stentless AVR [10]. In our analysis, no stentless 
bioprostheses were implanted.
At the time of publication, no standard objective patient 
selection criteria applied in our clinic for mini-AVR. The surgi-
cal approach was chosen by the individual surgeon. Therefore, 
Table 1. Relationship between the incidence of patient-prosthesis mismatch (PPM), mean effective orifice area index (EOAi), peak 
aortic valve gradient, and mean aortic valve and the prosthesis size
Aortic prosthesis size Mini-AVR (n = 74) Con-AVR (n = 76) p
No-PPM PPM No-PPM PPM
Small size [19 mm]: 33% (n = 1) 67% (n = 2) 40% (n = 2) 60% (n = 3) > 0.05
EOAi [cm2/m2] 0.99 0.75 ± 9.65 0.95 0.81 ± 0.01 > 0.05
Peak AVG [mmHg] 74 27 ± 0.71 36 ± 1.41 36 ± 11.53 > 0.05
Mean AVG [mmHg] 38 17 ± 1.41 18 ± 2.82 21 ± 5.29 > 0.05
Medium size [21 and 23 mm]: 58% (n = 37) 42% (n = 27) 79% (n = 46) 21% (n = 12) > 0.05
EOAi [cm2/m2] 1.01 ± 0.09 0.74 ± 0.09 1.09 ± 0.19 0.7 ± 0.7 0.007
Peak AVG [mmHg] 25.61 ± 14.18 26.6 ± 13.84 21.6 ± 8.95 29.56 ± 8.99 > 0.05
Mean AVG [mmHg] 15.47 ± 8.04 14.61 ± 4.67 12.6 ± 5.87 18.11 ± 6.17 > 0.05
Large size [27 mm]: 100% (n = 7) 0% (n = 0) 85% (n = 13) 15% (n = 2) > 0.05
EOAi [cm2/m2] 1.08 ± 0.11 – 1.18 ± 0.13 0.77 ± 0.03 > 0.05
Peak AVG [mmHg] 20.5 ± 3.27 – 18.01 ± 5.86 21 > 0.05
Mean AVG [mmHg] 11.71 ± 3.46 – 11.74 ± 5 15 > 0.05
Data are shown as mean ± standard deviation. AVG — aortic valve gradient; AVR — aortic valve replacement; con — conventional; mini — mini-
mally invasive
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it is possible that the higher frequency of PPM in mini-AVR is 
related to the surgeon learning the procedure.
Mini-AVR is associated with lower morbidity and mor-
tality in high-risk patients (e.g. obese and elderly) [12]. On 
the other hand, studies on PPM showed decreased survival 
rates in patients < 70 years of age and those with body mass 
index < 30 kg/m2, but not in elderly or obese patients [13]. 
This may mean that there is an even stronger need to moni-
tor mini-AVR procedures for PPM, because the benefits of 
this approach may be outweighed by the risk of worsened 
haemodynamics due to incorrect valve size.
This is a single-centre, non-randomised, retrospective 
study with a small patient sample size. The decision on the 
adopted method and the type and size of the implanted valve 
was a reflection of the individual surgeon’s preference.
In conclusion, the incidence of PPM was found to be 
higher in patients undergoing mini-AVR compared to those 
undergoing conventional sternotomy.
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